Patents by Inventor Yongxin Han

Yongxin Han has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Materials and methods to potentiate cancer treatment
    Patent number: 7179912
    Abstract: Compounds that inhibit DNA-dependent protein kinase, compositions comprising the compounds, methods to inhibit the DNA-PK biological activity, methods to sensitize cells the agents that cause DNA lesions, and methods to potentiate cancer treatment are disclosed.
    Type: Grant
    Filed: August 28, 2001
    Date of Patent: February 20, 2007
    Assignee: ICOS Corporation
    Inventors: James Halbrook, Edward A. Kesicki, Laurence E. Burgess, Stephen T. Schlachter, Charles T. Eary, Justin G. Schiro, Hongmei Huang, Michael Evans, Yongxin Han
  • EP4 receptor agonist, compositions and methods thereof
    Publication number: 20060270721
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Application
    Filed: August 2, 2006
    Publication date: November 30, 2006
    Inventors: Yongxin Han, John Colucci, Xavier Billot, Marie-Claire Wilson, Robert Young
  • Oxazolidin-2-one and thiazolidin-2-one derivatives for use as EPreceptor agonists in the treatment of glaucoma
    Patent number: 7109223
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Grant
    Filed: August 25, 2003
    Date of Patent: September 19, 2006
    Assignee: Merck & Co. Inc.
    Inventors: Yongxin Han, John Colucci, Xavier Billot, Marie-Claire Wilson, Robert Young
  • Ep4 receptor agonists
    Publication number: 20060167081
    Abstract: This invention relates to potent selective agonists of the EP, subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Application
    Filed: October 23, 2003
    Publication date: July 27, 2006
    Inventors: Xavier Billot, Jean-Luc Beaunard, Yongxin Han, Robert Young, John Colucci, Mario Girard, Marie-Claire Wilson
  • Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
    Publication number: 20060154899
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Application
    Filed: August 25, 2003
    Publication date: July 13, 2006
    Inventors: Yongxin Han, John Colucci, Xavier Billot, Marie-Claire Wilson, Robert Young
  • EP receptor agonist, compositions and methods thereof
    Patent number: 7053085
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Grant
    Filed: March 10, 2004
    Date of Patent: May 30, 2006
    Assignee: Merck & Co. Inc.
    Inventors: Xavier Billot, John Colucci, Yongxin Han, Marie-Claire Wilson, Robert N. Young
  • Irreversible caspase-3 inhibitors as active site probes
    Publication number: 20060069038
    Abstract: The present invention encompasses a compound of Formula (I) useful as caspase active site probes. These probes can be used to determine whether a caspase has been activated, in cells or in tissues of animal models of various pathologies. Furthermore, through competition based assays, these caspase active site probes can be used to calculate the percentage of occupancy of active caspases by other, unlabeled inhibitors.
    Type: Application
    Filed: February 5, 2004
    Publication date: March 30, 2006
    Inventors: John Colucci, Andre Giroux, Yongxin Han, Nathalie Methot, Donald Nicholson, Sophie Roy, John Vaillancourt, Paul Tawa
  • 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
    Publication number: 20050239872
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors of formula (1), their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of the patient.
    Type: Application
    Filed: June 2, 2003
    Publication date: October 27, 2005
    Inventors: Xavier Billot, Robert Young, Yongxin Han
  • EP4 receptor agonist, compositions and methods thereof
    Publication number: 20050227969
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Application
    Filed: June 7, 2005
    Publication date: October 13, 2005
    Inventors: Xavier Billot, John Colucci, Yongxin Han, Marie-Claire Wilson, Robert Young
  • AKT protein kinase inhibitors
    Publication number: 20050130954
    Abstract: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: November 19, 2004
    Publication date: June 16, 2005
    Inventors: Ian Mitchell, Keith Spencer, Peter Stengel, Yongxin Han, Nicholas Kallan, Mark Munson, Guy Vigers, James Blake, Anthony Piscopio, John Josey, Scott Miller, Dengming Xiao, Riu Xu, Chang Rao, Bin Wang, April Bernacki
  • EP4 receptor agonist, compositions and methods thereof
    Publication number: 20040198701
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Application
    Filed: March 10, 2004
    Publication date: October 7, 2004
    Inventors: Xavier Billot, John Colucci, Yongxin Han, Marie-Claire Wilson, Robert N. Young
  • Pyrazinones, compositions containing such compounds and methods of use
    Patent number: 6699856
    Abstract: Compounds represented by formula I: as well as pharmaceutically acceptable salts, esters, N-oxides and hydrates thereof are disclosed. Pharmaceutical compositions and methods of use are also included. The compounds are active against the caspase-3 enzyme, and thus are useful to treat caspase-3 mediated diseases and conditions.
    Type: Grant
    Filed: July 25, 2002
    Date of Patent: March 2, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Yongxin Han, Andre Giroux, Robert Zamboni, Daniel J. McKay, Christopher I. Bayly, Erich L. Grimm, John Colucci
  • Pyrazinones, compositions containing such compounds and methods of use
    Publication number: 20030236402
    Abstract: Compounds represented by formula I: 1
    Type: Application
    Filed: July 25, 2002
    Publication date: December 25, 2003
    Applicant: Merck Frosst Canada & Co.
    Inventors: Yongxin Han, Andre Giroux, Robert Zamboni, Daniel J. McKay, Christopher I. Bayly, Erich L. Grimm, John Colucci
  • Gamma-ketoacid dipeptide derivatives as inhibitors of caspase-3
    Publication number: 20030045478
    Abstract: This invention encompasses the novel compounds of Formula I, which are useful in the treatment of caspase-3 mediated diseases.
    Type: Application
    Filed: December 14, 2001
    Publication date: March 6, 2003
    Inventors: Yongxin Han, Renee Aspiotis, Andre Giroux, Erich L. Grimm, Christophe Mellon, Robert Zamboni, Christopher I. Bayly
  • Gamma-ketoacid dipeptides as inhibitors of caspase-3
    Patent number: 6525025
    Abstract: This invention encompasses the novel compounds of Formula I, which are useful in the treatment of caspase-3 mediated diseases. The invention also encompasses certain pharmaceutical compositions comprising compounds of Formula I as well as methods for treatment of caspase-3 mediated diseases.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: February 25, 2003
    Assignee: Merck Frosst Canada & Co.
    Inventors: Yongxin Han, Andre Giroux, Erich L. Grimm, Renee Aspiotis, Cameron Black
  • Materials and methods to potentiate cancer treatment
    Publication number: 20020165218
    Abstract: Compounds that inhibit DNA-dependent protein kinase, compositions comprising the compounds, methods to inhibit the DNA-PK biological activity, methods to sensitize cells the agents that cause DNA lesions, and methods to potentiate cancer treatment are disclosed.
    Type: Application
    Filed: August 28, 2001
    Publication date: November 7, 2002
    Inventors: James Halbrook, Edward A. Kesicki, Laurence E. Burgess, Stephen T. Schlachter, Charles T. Eary, Justin G Schiro, Hongmei Huang, Michael Evans, Yongxin Han
  • Gamma-ketoacid dipeptides as inhibitors of caspase-3
    Publication number: 20020165230
    Abstract: This invention encompasses the novel compounds of Formula I, which are useful in the treatment of caspase-3 mediated diseases.
    Type: Application
    Filed: September 7, 2001
    Publication date: November 7, 2002
    Inventors: Yongxin Han, Andre Giroux, Erich L. Grimm, Renee Aspiotis, Cameron Black
  • Pyrazinones, compositions containing such compounds and methods of use
    Patent number: 6444811
    Abstract: Compounds represented by formula I: as well as pharmaceutically acceptable salts, esters, N-oxides and hydrates thereof are disclosed. Pharmaceutical compositions and methods of use are also included. The compounds are active against the caspase-3 enzyme, and thus are useful to treat fin caspase-3 mediated diseases and conditions.
    Type: Grant
    Filed: July 19, 2000
    Date of Patent: September 3, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Yongxin Han, Andre Giroux, Robert Zamboni, Daniel J. McKay, Christopher I. Bayly, Erich L. Grimm, John Colucci
  • Gamma-ketoacid dipeptides as inhibitors of caspase-3
    Patent number: 6225288
    Abstract: Compounds represented by formula I: as well as pharmaceutically acceptable salts, esters and hydrates thereof are disclosed along with pharmaceutical compositions and methods of treatment. The compounds are useful as inhibitors of caspase-3, which is implicated in modulating apoptosis.
    Type: Grant
    Filed: March 16, 2000
    Date of Patent: May 1, 2001
    Assignee: Merk Frosst Canada & Co.
    Inventors: Yongxin Han, Andre Giroux, Erich Grimm, Renee Aspiotis, Sebastien Francoeur, Robert Zamboni, Petpiboon Prasit, Christopher Bayly, Dan McKay, Cameron Black
  • Prostaglandin conjugates for treating or preventing bone disease
    Patent number: 6121253
    Abstract: This invention relates to prostaglandin-bisphosphonate conjugates. These conjugates are effective for treating or preventing bone diseases such as osteoporosis. These conjugates simultaneously deliver a prostaglandin agent for increasing bone formation and a bisphosphonate agent for inhibiting bone resorption.
    Type: Grant
    Filed: November 15, 1999
    Date of Patent: September 19, 2000
    Assignee: Merck Frosst Canada & Co.
    Inventors: Yongxin Han, Robert N. Young, Laurent Gil, Rejean Ruel